A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs JNJ 61186372 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 Jul 2017 Planned number of patients changed from 40 to 90.
    • 04 Jul 2017 Planned End Date changed from 19 Oct 2018 to 2 Mar 2020.
    • 04 Jul 2017 Planned primary completion date changed from 5 Oct 2018 to 2 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top